Genomic Health, Inc.  

(Public, NASDAQ:GHDX)   Watch this stock  
Find more results for GHDX
33.06
-0.11 (-0.33%)
After Hours: 33.06 0.00 (0.00%)
Nov 24, 5:11PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 32.94 - 33.88
52 week 23.90 - 37.74
Open 33.16
Vol / Avg. 96,594.00/151,492.00
Mkt cap 1.05B
P/E     -
Div/yield     -
EPS -0.89
Shares 31.72M
Beta 0.59
Inst. own 96%
Feb 2, 2015
Q4 2014 Genomic Health Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 11, 2014
Genomic Health Inc at Credit Suisse Healthcare Conference
Nov 4, 2014
Q3 2014 Genomic Health Inc Earnings Call
Nov 4, 2014
Q3 2014 Genomic Health Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -9.06% -4.88%
Operating margin -8.44% -4.77%
EBITD margin - -2.11%
Return on average assets -14.06% -7.71%
Return on average equity -17.50% -9.40%
Employees 684 -
CDP Score - -

Address

301 Penobscot Drive
REDWOOD CITY, CA 94063
United States - Map
+1-650-5569300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Genomic Health, Inc. (Genomic Health) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.

Officers and directors

Kimberly J. Popovits Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
G. Bradley Cole Chief Financial Officer, Chief Operating Officer, Principal Financial Officer, Principal Accounting Officer
Age: 58
Bio & Compensation  - Reuters
Steven Shak M.D. Executive Vice President - Research and Development
Age: 63
Bio & Compensation  - Reuters
Julian C. Baker Lead Independent Director
Age: 48
Bio & Compensation  - Reuters
Henry J. Fuchs M.D., Ph.D. Director
Age: 56
Bio & Compensation  - Reuters
Felix J. Baker Ph.D. Independent Director
Age: 45
Bio & Compensation  - Reuters
Fred E. Cohen Ph.D., M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Samuel D. Colella Independent Director
Age: 74
Bio & Compensation  - Reuters